ARK Invest's position in NTLA, updated every trading day. Data as of 2026-11-12.
| Fund | Shares | Value | Weight | Rank |
|---|---|---|---|---|
| ARKK | 14,063,687 | $148.4M | 2.04% | #20 |
| ARKG | 3,497,291 | $36.9M | 1.87% | #20 |
| Trade day | Fund | Side | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-27 | ARKG | Buy | Added | 37,586 | $462K |
| 2026-10-12 | ARKG | Buy | Added | 32,596 | $410K |
| 2026-10-09 | ARKG | Buy | Added | 48,171 | $630K |
| 2026-10-06 | ARKK | Buy | Added | 57,055 | $706K |
| 2026-10-06 | ARKG | Buy | Added | 14,549 | $180K |
| 2026-10-05 | ARKK | Buy | Added | 77,291 | $985K |
| 2026-10-05 | ARKG | Buy | Added | 19,017 | $242K |
| 2026-10-02 | ARKK | Buy | Added | 410,738 | $5.0M |
| 2026-10-02 | ARKG | Buy | Added | 100,959 | $1.2M |
| 2026-10-01 | ARKK | Buy | Added | 321,950 | $3.9M |
| 2026-10-01 | ARKG | Buy | Added | 88,961 | $1.1M |
| 2026-09-30 | ARKK | Buy | Added | 365,479 | $4.4M |
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated 9 (Cas9) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases.…
See NTLA's full ARK history since 2024, ARK's estimated cost basis, the conviction score and buy/sell alerts.
Open NTLA on FundWake →Data comes from ARK Invest's public daily holdings and trade files. FundWake is not affiliated with ARK Invest. Nothing here is investment advice.